Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection-Reference-Cited by-同舟云学术

Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Published:2022-03-10 Issue:1 Volume:75 Page:e525-e528
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

FitzGerald Richard¹,Dickinson Laura²,Else Laura²,Fletcher Thomas³,Hale Colin¹,Amara Alieu²,Walker Lauren¹,Penchala Sujan Dilly²,Lyon Rebecca¹,Shaw Victoria²,Greenhalf William²,Bullock Katie²,Lavelle-Langham Lara²,Reynolds Helen²,Painter Wendy⁴,Holman Wayne⁴,Ewings Sean⁵,Griffiths Gareth⁵,Khoo Saye¹²

Affiliation:

1. National Institute for Health Research Royal Liverpool & Broadgreen Clinical Research Facility, Liverpool University Hospital NHS Foundation Trust , Liverpool , United Kingdom

2. Department of Pharmacology & Therapeutics, University of Liverpool , Liverpool , United Kingdom

3. Department of Clinical Sciences, Liverpool School of Tropical Medicine , Liverpool , United Kingdom

4. Ridgeback Biotherapeutics , Miami, Florida , USA

5. National Institute for Health Research Southampton Clinical Trials Unit, University of Southampton , Southampton , United Kingdom

Abstract

Abstract ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at SARS-CoV-2 transmission sites in 12 patients enrolled in AGILE Candidate-Specific Trial-2. Saliva, nasal, and tear NHC concentrations were 3%, 21%, and 22% that of plasma. Saliva and nasal NHC were significantly correlated with plasma (P < .0001). Clinical Trials Registration. NCT04746183.

Funder

Medical Research Council

Wellcome Trust

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac199/43525040/ciac199.pdf

Reference12 articles.

1. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal Venezuelan equine encephalitis virus infection;Painter;Antiviral Res,2019

2. AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter;Griffiths;Trials,2021